tirzepatide for the treatment of obstructive sleep apnea and obesity FDA has just approved Zepbound (tirzepatide), the first medication designed to treat both apnoea (OSA) simultaneously. In clinical trials, Zepbound helped reduce breathing disruptions by 50% and #VisualAbstract: Tirzepatide Improved Outcomes in

Because PlexusDx does not route medications through insurance, patients avoid prior authorization delays, coverage denials, and formulary restrictions entirely

Over time, untreated rheumatoid arthritis causes joint damage and may result in serious disability

But people without diabetes who are taking GLP-1s may experience gastroparesis, as well

A clinician review of patients medical waivers is always required before starting

The active engagement in longevity goals varies by generation, though, which is important for technology and consumer products developers to understand

It is important to be active and exercise if you can, eat properly, and minimize stress so that you can see the best results